1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with Disease Models, Animal in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsaeedi, N; Bandaru, VV; Chatterjee, S; Halushka, MK; Haughey, NJ; Hou, J; Ndikuyeze, G; Pili, R; Wu, L | 1 |
| Butters, TD; Dwek, RA; Jeyakumar, M; Platt, FM | 1 |
| Hisaki, H; Kubota, M; Masuda, H; Nakagomi, T; Nakane, M; Shimasaki, H; Tamura, A; Ueta, N | 1 |
| Anada, Y; Anderson, DW; Bradbury, KA; Inokuchi, J; Schneider, JS | 1 |
| Brady, RO; Brown, A; Comly, ME; Cooney, A; Goldin, E; Miller, SP; Pentchev, PG; Roff, CF; Vanier, MT | 1 |
2 review(s) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Disease Models, Animal
| Article | Year |
|---|---|
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Topics: 1-Deoxynojirimycin; Animals; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Disease Models, Animal; G(M2) Ganglioside; Gangliosides; Glucosylceramides; Glucosyltransferases; Glycosphingolipids; Humans; Lysosomal Storage Diseases; Lysosomes; Mice; Models, Biological; Models, Chemical; Morpholines; Sandhoff Disease; Tay-Sachs Disease; Treatment Outcome | 2002 |
Type C Niemann-Pick disease: use of hydrophobic amines to study defective cholesterol transport.
Topics: Amines; Androstenes; Animals; Biological Transport; Cells, Cultured; Cholesterol; Cholesterol Esters; Disease Models, Animal; Fibroblasts; Filipin; Humans; Imipramine; Lysosomes; Mice; Morpholines; Niemann-Pick Diseases; Sphingosine; Structure-Activity Relationship | 1991 |
3 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Disease Models, Animal
| Article | Year |
|---|---|
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
Topics: Administration, Oral; Animals; Antigens, CD; Blotting, Western; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Galactosyltransferases; Glucosylceramides; Glucosyltransferases; Kidney; Kidney Neoplasms; Lactosylceramides; Mice; Mice, Inbred BALB C; Morpholines; Peptide Fragments; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; Transcription Factors; Treatment Outcome; Tumor Burden; Tumor Suppressor Protein p53 | 2013 |
In vivo influence of ceramide accumulation induced by treatment with a glucosylceramide synthase inhibitor on ischemic neuronal cell death.
Topics: Animals; Brain Ischemia; Cell Death; Ceramides; Disease Models, Animal; Enzyme Inhibitors; Gerbillinae; Glucosylceramides; Glucosyltransferases; Hippocampus; Male; Morpholines; Nerve Degeneration; Sphingosine | 2004 |
The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism.
Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Morpholines; Neurons; Parkinsonian Disorders | 2006 |